2021
DOI: 10.1080/15563650.2021.1994144
|View full text |Cite
|
Sign up to set email alerts
|

Involuntary MDMB-4en-PINACA intoxications following cannabis consumption: clinical and analytical findings

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
5
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(5 citation statements)
references
References 26 publications
0
5
0
Order By: Relevance
“…There are now (July 2023) 44 scientific articles in all (40 entries in Pubmed, 41 in Scopus, and 37 in Web of Science), but none of these describe a fatal case in detail, and only one describes the symptoms linked with its usage. Goncalves et al reported eight cases of MDMB-4en-PINACA associated hospitalization with the most common symptoms of paranoia and/or hallucinations (four cases), nausea and/or vomiting (three cases), altered or loss of consciousness (three cases), psychomotor agitation and/or aggressiveness (three cases), headaches (three cases), persistent tiredness (three cases), mydriasis (three cases), seizure (two cases), amnesia (two cases), and dizziness (two cases) [ 29 ]. Seizures after consumption of MDMB-4-en-PINACA were also reported [ 30 ].…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…There are now (July 2023) 44 scientific articles in all (40 entries in Pubmed, 41 in Scopus, and 37 in Web of Science), but none of these describe a fatal case in detail, and only one describes the symptoms linked with its usage. Goncalves et al reported eight cases of MDMB-4en-PINACA associated hospitalization with the most common symptoms of paranoia and/or hallucinations (four cases), nausea and/or vomiting (three cases), altered or loss of consciousness (three cases), psychomotor agitation and/or aggressiveness (three cases), headaches (three cases), persistent tiredness (three cases), mydriasis (three cases), seizure (two cases), amnesia (two cases), and dizziness (two cases) [ 29 ]. Seizures after consumption of MDMB-4-en-PINACA were also reported [ 30 ].…”
Section: Resultsmentioning
confidence: 99%
“…Xiang et al also identified further ketone metabolites and special phase II metabolites [ 28 ]. Various clinical symptoms were reported after using MDMB-4en-PINACA, such as headaches, seizures, paranoia, anxiety, hallucinations, amnesia, mydriasis, nausea, and vomiting [ 29 , 30 ].…”
Section: Introductionmentioning
confidence: 99%
“…3,15,16 Among the drug class, MDMB-4en-PINACA is a newer generation compound that has recently emerged, probably with a toxicity profile like the drug class in general. 17,18 Although other toxic effects such as seizures, psychiatric symptoms, and gastrointestinal symptoms have been described with synthetic cannabinoid use, the most significant and potentially lethal toxicities are cardiovascular in nature, particularly arrhythmias, cardiac arrest, and myocardial ischemia. These effects are thought to be mediated by the highly potent activation of cannabinoid receptor 1 by synthetic cannabinoids in comparison with the only partial agonist effects on this receptor by tetrahydrocannabinol found in marijuana, although downstream details of this activation are not well understood.…”
Section: Discussionmentioning
confidence: 99%
“…This is in part due to their potentially lethal toxic adverse effects, as well as their frequently evolving chemical makeup, which renders their toxicologic identification and monitoring more difficult 3,15,16 . Among the drug class, MDMB-4en-PINACA is a newer generation compound that has recently emerged, probably with a toxicity profile like the drug class in general 17,18 . Although other toxic effects such as seizures, psychiatric symptoms, and gastrointestinal symptoms have been described with synthetic cannabinoid use, the most significant and potentially lethal toxicities are cardiovascular in nature, particularly arrhythmias, cardiac arrest, and myocardial ischemia.…”
Section: Discussionmentioning
confidence: 99%
“…With a positivity rate of 3.6%, synthetic cannabinoids appear not to be 'niche drugs' anymore. Furthermore, there is a growing concern that traditional consumers of cannabis may be at risk of inadvertent exposure to synthetic cannabinoids [54][55][56][57].…”
Section: Europementioning
confidence: 99%